Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205).
Michael K GibsonPaul CatalanoLawrence R KleinbergCharles A StaleyElizabeth A MontgomeryAntonio JimenoWei Frank SongMary F MulcahyLawrence P LeichmanAl B BensonPublished in: The oncologist (2019)
Esophageal cancer is a disease with a high death rate. The current treatment involves giving chemotherapy plus radiation followed by surgery, but this cures only a quarter of patients. In order to improve survival, better treatments are needed. This trial evaluated the addition of a novel drug, cetuximab, to chemotherapy plus radiation. Unfortunately, the side effects were too great and the study was stopped early.
Keyphrases
- locally advanced
- phase ii study
- rectal cancer
- squamous cell carcinoma
- radiation therapy
- end stage renal disease
- patients undergoing
- study protocol
- phase iii
- clinical trial
- ejection fraction
- newly diagnosed
- minimally invasive
- peritoneal dialysis
- prognostic factors
- radiation induced
- papillary thyroid
- phase ii
- emergency department
- randomized controlled trial
- acute coronary syndrome
- coronary artery disease
- young adults
- atrial fibrillation
- percutaneous coronary intervention
- drug induced
- lymph node metastasis
- surgical site infection